14.02.2018 • NewsElaine Burridgepetchem

Shaheen Plans $1 billion Petchem Complex in UAE

Shaheen Chem Investment, is planning to invest Dh4 billion, or around $1...
Shaheen Chem Investment, is planning to invest Dh4 billion, or around $1 billion, to build a chemical complex in Abu Dhabi. (c) mmmx/Shutterstock

Shaheen Chem Investment, owned by investors from the United Arab Emirates (UAE) and Oman, is planning to invest Dh4 billion, or around $1 billion, to build a chemical complex in Abu Dhabi.

The company has signed an agreement with the Khalifa Industrial Zone of Abu Dhabi (Kizad) to lease land for a two-stage complex that is intended to support the UAE’s expanding chemical industry.

In a first phase, Shaheen will build a plant to produce 130,000 t/y of caustic soda and 160,000 t/y of ethylene dichloride (EDC). The facility will supply caustic soda raw material to the Al Taweelah alumina refinery operated by Emirates Global Aluminium (EGA).

The second phase will include a doubling of caustic soda capacity and extending operations to include production of vinyl chloride and PVC. A timescale for both stages of the project was not disclosed.

Shaheen’s chairman, Rashed Al Suwaidi, said the company was excited to become the first producer of EDC in the UAE.

The zone is reported to have attracted investors from countries such as China, Japan, India and Brazil among others since it opened in 2012.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.